Importantly, we were able to use this protocol to identify two NSCLC patients who developed G1202R point mutations as a mechanism of resistance to ALK-TKIs or G1202R mutation detected during treatment with crizotinib and it was not associated with resistance to this drug. Here, ALK is linked to non-small cell lung carcinoma.